Here's Why TimesSquare Mid Cap Growth Strategy Added Insmed (INSM)
TimesSquare Capital Management, an equity investment management company, released its “U.S.
Insmed Inc (INSM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Darwin Global Management Abhishek Trehan | 16,805,184 | $2,576,570,811 | -20% | 68.33% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 7,421,111 | $1,213,500,071 | +13% | 6.97% |
| 3. | D E Shaw D. E. Shaw | 5,625,825 | $919,934,904 | +30% | 0.55% |
| 4. | Citadel Investment Group Ken Griffin | 2,182,571 | $356,894,010 | +89% | 0.06% |
| 5. | Orbis Investment Management William B. Gray | 1,872,824 | $306,244,181 | -56% | 1.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $66.35 | 1,130 | $74,975.50 | 3,025 | 2025-05-21 | Filing | |
| $66.87 | 1,895 | $126,718.65 | 1,895 | 2025-05-20 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 10,000 | 2023-05-15 | Filing | |
| $19.29 | 10,000 | $192,900.00 | 298,615 | 2023-05-15 | Filing | |
| $17.70 | 10,000 | $177,000.00 | 15,900 | 2022-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $106.27 | 1,292 | $137,300.84 | 258,917 | 2026-06-25 | Filing | |
| $105.27 | 2,456 | $258,543.12 | 260,209 | 2026-06-25 | Filing | |
| $104.28 | 3,723 | $388,234.44 | 262,665 | 2026-06-25 | Filing | |
| $103.10 | 1,836 | $189,291.60 | 266,388 | 2026-06-25 | Filing | |
| $102.34 | 12,091 | $1,237,392.94 | 268,224 | 2026-06-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 296 | $31,560 | 0% | |
| 2. | 187 | $19,938 | 0% | |
| 3. | 173 | $18,445 | 0% | |
| 4. | 118 | $12,581 | 0% | |
| 5. | 32 | $3,412 | 0% |
News See All
10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds
On June 9, Reuters reported that Philips' Future Health Index survey concluded that artificial intelligence improved clinical accuracy and increased patient capacity.
10 Most Promising Healthcare Stocks According to Wall Street Analysts
The US healthcare sector has trailed the broader market for three consecutive years, returning just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller
What sets billionaire Stanley Druckenmiller apart from other Wall Street giants is his frankness, humility, and openness to learn.
11 Best Long Term US Stocks to Buy Right Now
The Franklin Templeton report said long-term investing has usually rewarded patient investors. Markets go through rough periods, as recessions and bear markets happen.
10 Stocks With Stunning Gains
Ten stocks boasted strong gains on Tuesday, outperforming a lackluster performance on Wall Street, as investors continued to digest a flurry of strong corporate earnings.
8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Insmed Incorporated (NASDAQ:INSM) Q1 2026 Earnings Call Transcript
Operator: Thank you for standing by. My name is Danica, and I will be your conference operator today.
Billionaire Druckenmiller and Jim Cramer Like These Stocks
Stanley Druckenmiller and Jim Cramer are two of the closely followed voices in financial markets. Though sometimes their stock preferences differ, they always draw widespread investor attention.
Insmed Incorporated (INSM) PT Lifted to $230 as Guggenheim Updates Biotech Earnings Models
TheFly reported on April 16 that Guggenheim Securities increased its price target on INSM from $227 to $230 while maintaining a Buy rating.